BEROCCA® Express effervescent tablets

Dosage form Application area Recommendations for use Contraindications Manufacturer
Read on
Certificate number:RU.77.99.11.003.Е.001239.03.17
Date of registration and renewal:16.03.2017
Dosage form: & nbspEffervescent tablets weighing 4800 mg ± 5%.
Classification "Composition" & nbsp BAD - vitamin and mineral complexes Supplements - macro and microelements BAD - products of plant, animal or mineral origin
Classification "Clinical" & nbsp BAD-sources of multivitamins containing individual minerals and mineral complexes BAD-sources of vitamin-mineral complexes Supplements containing potassium and magnesium Supplements containing zinc, copper, manganese Supplements containing calcium and phosphorus
Composition: & nbspE330, E500ii, calcium carbonate, E420, magnesium sulphate dihydrate, guarana seed extract, aroma food "Acerola" (fragrance substances, dextrin, E414), magnesium carbonate, E421, dye beet juice powder, ascorbic acid, E500i, caffeine, nicotinamide, zinc citrate, E951, E950, calcium pantothenate, pyridoxine hydrochloride, riboflavin, E955, thiamine monophosphate chloride, E435, folic acid, biotin, cyanocobalamin.
Scope: & nbspTo realize the population as a biologically active food additive - an additional source of vitamins B1, B2, B3 (nicotinamide), B5 (pantothenic acid), B6, B9 (folic acid), B12, H (biotin), C, magnesium, zinc, caffeine, containing calcium.
Suggested Usage: & nbspAdults take 1 tablet in the morning during meals, previously dissolved in a glass of water. Duration of admission is 1 month.
Contraindications:Individual intolerance of components, pregnancy, breast-feeding, increased nervous excitability, insomnia, arterial hypertension, phenylketonuria.
Special instructions:Before use, it is recommended to consult a doctor.
Shelf life:36 months.
Storage conditions:Keep out of the reach of children, at a temperature of no higher than 30 ° C.
Research protocols:Expert conclusion of the NII NII NII / E-177 / b-16 from 03.03.2016, the protocol of the testing center of the Test Center of Medicines Biotechnology No. T16-02785 of August 24, 2016.
Recipient:Bayer, AOBayer, AO Russia
Information update date: & nbsp05.04.2017
Instructions
Up